Condition: Mycobacterium Avium Complex Pulmonary Disease · Sponsor: Bin Cao
The goal of this clinical trial is to learn if contezolid works to treat mycobacterium avium complex pulmonary disease in adults. It will also learn about the safety of contezolid. The main questions it aims to answer are: Does adding contezolid to standard regimen further decrease the bacterial load in patients' sputum compared with current standard regimen? What medical problems do participants have when taking contezolid along with standard regimen? Researchers will compare standard regimen plus contezolid to standard regimen alone to see if contezolid helps further lower the count of bacteria in patients' sputum. Participants will: Take contezolid and standard regimen (azithromycin, ethambutol and rifampicin) or standard regimen only for 6 months, contezolid is administered every day while other drugs are taken 3 times a week Visit the clinic once every 1 month for checkups and tests.
This description comes directly from the study's public registry record.
Siwei Gu, M.D. · 86 10 84205566 · orbitline2@gmail.com
Always discuss trial participation with your own doctor first.
| Beijing Chest Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Active Not Recruiting |
| China-Japan Friendship Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Jiangxi Provincial Chest Hospital | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07084402